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Factors predicting walking intolerance in patients with 
peripheral arterial disease and intermittent claudication
B Parr, T D Noakes, E W Derman
Peripheral arterial disease (PAD) is a complex disease with 
patients typically suffering from hypertension, diabetes and 
coronary artery disease (CAD). Risk factors for PAD include 
smoking, hypercholestrolaemia, male gender and age.1 Patients 
with PAD are walking intolerant.
The cause of walking intolerance in patients with PAD 
is not clear. It has been suggested that a compromised 
oxidative metabolism accelerates lactate accumulation in the 
exercising skeletal muscles, inducing the pain of intermittent 
claudication.2,3 Studies have shown that improvements in 
walking tolerance with exercise training are associated with 
increases in the concentration of skeletal muscle oxidative 
enzymes2,4,5 and improved oxygen extraction by the trained 
skeletal muscles.6,7 These findings have served to reinforce the 
hypothesis that skeletal muscle anaerobiosis causing increased 
lactate production in the ischaemic exercising skeletal muscles 
causes the pain of claudication.
Other researchers have suggested that walking intolerance 
results primarily from decreased blood flow to the lower limb 
so that improvements in blood flow as a result of a training-
induced increase in collateral circulation enhance walking 
tolerance in patients with PAD.8-10 Therefore the ankle brachial 
index (ABI) is a commonly used clinical measure to predict the 
functional capacity of patients with this complaint.
Our main objective was to examine the relationship between 
peak physiological parameters measured during symptom-
limited maximal exercise and the walking tolerance of patients 
with PAD. We postulated that certain physiological parameters 
(in particular, high venous blood lactate concentrations and a 
low ABI, both indicating a reduced capacity for blood flow to 
the exercising skeletal muscles, thus causing an early onset of 
ischaemia) would predict their walking distance. A secondary 
objective was to report the demographical and medical 
characteristics of 31 patients with PAD.
Methods
Participants
Thirty-one patients with PAD were recruited from the 
Department of Vascular Surgery at Groote Schuur Hospital, 
and from Kingsbury Hospital, Claremont, Cape Town. All 
patients had PAD with intermittent claudication, as diagnosed 
by a vascular surgeon using duplex flow Doppler and/or 
segmental Doppler pressures. For inclusion, patients had to 
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Objective. To determine which physiological variables conduce 
to walking intolerance in patients with peripheral arterial 
disease (PAD).
Design. The physiological response to a graded treadmill 
exercise test (GTT) in patients with PAD was characterised.
Setting. Patients were recruited from the Department of 
Vascular Surgery, Groote Schuur Hospital, Cape Town.
Subjects. Thirty-one patients diagnosed with PAD were 
included in the study.
Outcome measures. During a GTT, peak oxygen consumption 
(VO2peak), peak minute ventilation (VEpeak), peak heart rate 
and peak venous lactate concentrations were measured 
and compared with those from a comparison group. Ankle-
brachial index (ABI) was measured at rest and after exercise. 
During the GTT, maximum walking distance (MWD) and 
pain-free walking distance (PFWD) were measured to 
determine walking tolerance.
Results. Peak venous lactate concentrations did not correlate 
significantly with either PFWD (r=–0.08; p=0.3) or MWD 
(r=–0.03; p=0.4). Resting ABI did not correlate with either 
MWD (r=0.09; p=0.64) or PFWD (r=–0.19; p=0.29). Subjects 
terminated exercise at significantly (p<0.05) lower levels of 
cardiorespiratory effort and venous lactate concentrations 
than did a sedentary but otherwise healthy comparison 
group: peak heart rate 156±11 v. 114±22 beats per minute 
(BPM); p=0.001; and peak venous lactate concentration 9.7±2.7 
mmol/l v. 3.28±1.39 mmol/l; p=0.001.
Conclusion. Perceived discomfort in these patients is not 
caused by elevated blood lactate concentrations, a low ABI 
or limiting cardiorespiratory effort but by other factors not 
measured in this study.
S Afr Med J 2008; 98: 958-962.
December 2008, Vol. 98, No. 12  SAMJ
959
develop intermittent claudication during a screening treadmill 
test and to have an ABI at rest of less than 0.97 or a fall of the 
ABI to <0.85 during exercise. Patients were excluded if any of 
the following were present: absence of PAD; rest pain or tissue 
loss; limitations of exercise tolerance caused by conditions 
other than claudication (e.g. severe CAD, dyspnoea, severe 
arthritis); and active cancer, liver or renal disease. Patients 
gave their written informed consent. The study protocol was 
approved by the Ethics and Research Committee of the Faculty 
of Health Sciences of the University of Cape Town.
Measurements
On the first visit to the laboratory, a full anthropometric 
analysis was performed for determination of body 
composition, a full medical history was taken and medical 
records were obtained from the vascular surgeon and 
cardiologist. Patients were familiarised with the treadmill 
protocol.
Exercise test
On the second visit, patients performed a graded treadmill 
exercise test (GTT) to measure physiological variables during 
maximal exercise. During the GTT, the speed was held constant 
at 3.2 km/h with an initial 2% gradient.11 The gradient was 
then increased by 2% every 2 minutes. If unable to walk at that 
speed, subjects were tested using the Modified Bruce protocol 
in which the treadmill speed was held constant at 1.7 km/h. 
Heart rate and brachial artery blood pressure were monitored 
every 2 minutes. Patients reported their level of perceived 
pain according to a perception of pain scale12 that uses simple-
to-understand verbal expressions which accurately describe 
sensations of perceived peripheral pain. Pain-free walking 
distance (PFWD) was recorded as the distance walked before 
the patient first reported calf pain during exercise. Maximum 
walking distance (MWD) was defined as the distance covered 
on the treadmill until the patient voluntarily terminated 
exercise as a result of severe claudication pain that could not be 
tolerated.
During exercise, inspiratory ventilation rate (VE), oxygen 
uptake (VO2) and respiratory exchange ratio (RER) were 
measured over 15-second intervals by breath-by-breath Oxycon 
Alpha Analyzer (Oxycon Alpha, Enrich Jaeger, Wuerzburg, 
Germany). Before each test, the gas meter was calibrated with a 
Hans Rudolph 3-litre syringe (Vacumed, Ventura, California), 
and the analysers were calibrated with room air and a 4% CO2 - 
16% O2 - 80% N2 gas mixture. The reliability of the Oxycon 
Alpha Analyzer was tested weekly by burning ethanol (99% 
analytical reagent, Associated Chemical Enterprises, Glenvista, 
South Africa) as a reference. Heart rate during the GTT was 
recorded using an electrocardiogram monitor (Cardio Perfect 
3.3, Rijswijk, the Netherlands) with self-adhering electrodes 
placed in a modified 10-electrode (Mason-Likar) configuration.8
Blood pressure
Before the treadmill test, subjects remained supine in a quiet 
environment for 15 minutes and the resting brachial blood 
pressure (Korotkoff phase I and IV) was measured and 
recorded by means of audible sphygmomanometry using 
a calibrated mercury column sphygmomanometer with 
an appropriately sized cuff. Simultaneously, another tester 
measured left and right ankle pressures consecutively with a 
Doppler (Huntleigh Technology PLC 1997 Dopplex Advanced 
Pocket Dopplers, UK) and blood pressure cuffs affixed just 
above the ankles. The Doppler probe was placed over the 
posterior tibial or dorsalis pedis artery. The cuff was inflated 
until the Doppler sound disappeared, and slowly deflated until 
the sound returned. The ankle systolic pressure was measured 
when the sound returned. ABI was calculated for each patient 
by dividing the ankle pressure reading by the brachial pressure 
reading. The procedure was repeated immediately after 
exercise.
Blood sample analysis
Before the start of the treadmill test, a resting venous blood 
sample was drawn from each patient; 2 ml of blood was 
drawn directly into a sodium oxalate-lined glass test tube 
and immediately placed on ice for later analysis of plasma 
lactate concentrations; and a 2 ml blood sample was collected 
3 minutes after exercise when the blood lactate concentration 
peaks.13
The 2 ml blood samples in the sodium oxalate test tubes 
were centrifuged using a Sigam 302-K centrifuge (Munich, 
Germany) at 3 000 rpm for 10 minutes at 4°C. Blood lactate 
concentrations were measured in plasma by means of an 
enzymatic kit technique (bioMerieux SA, lactate PAP 69280, 
Marcy l’Etoille, France).
Statistical analysis
Data are presented as means ±SD. Correlation coefficients 
within the patient population were calculated by means 
of Pearson’s product moment correlation coefficient for 
continuous data using Statistica (StatSoft Inc., Tulsa, USA). 
Levels of significance were calculated at the 0.05 confidence 
levels. In the cases of correlations, correlation coefficients were 
denoted as r and the sample size as N. A dependent t-test was 
used to assess differences between pre-exercise venous lactate 
concentrations and post-exercise lactate concentrations. Ratings 
of pain taken every 2 minutes during the exercise tests were 
converted to a single variable for each patient by plotting 
an area under the curve for each patient. The data were 
normalised by expressing the pain measure (Y axis) relative to 
100% of elapsed time (X axis). Independent t-tests were used to 
detect differences between means of this sample group and the 
comparison group from this laboratory.
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Results
General and medical characteristics of patients are detailed in 
Tables I and II.
The mean MWD during the GTT was 317 m; pain-free 
walking distance was 98 m (Table I). Of significance is that 45% 
of patients with PVD also had clinical evidence for CAD, 81% 
had hypertension, 48% had hypercholesterolaemia and 40% 
had diabetes (Table II).
We were unable to develop an age-matched control group 
of apparently healthy individuals without PVD. The findings 
were therefore compared with data collected from a previous 
study in this laboratory of a sedentary but otherwise healthy 
middle-aged control group (CONT23 – Table III). The CONT 
group had higher peak VO2, VE, HR and RER values and peak 
lactate concentrations than patients with PVD (Table III).
There was no correlation between peak post-exercise venous 
lactate concentrations and PFWD (r=–0.08; p=0.33) or MWD 
(r=–0.03; p=0.44) during the GTT (Figs 1a and 1b).
There was a trend for ABI to drop after the GTT (0.6±0.4 
v. 0.4±0.4 pre-exercise to post exercise, p=0.056) (Table I). 
However, resting ABI did not correlate with MWD (r=0.08; 
p=0.3) or pain-free walking distance (r=–0.19; p=0.15) (Figs 2a 
and 2b); nor was there any relationship between post-exercise 
ABI and walking tolerance during the GTT. Predictably, 
VO2peak (r=0.68; p=0.001) and Vepeak (r=0.5; p=0.005) correlated 
significantly with MWD during the treadmill exercise test.
No significant correlations were found between age, BMI, 
fat percentage, duration of disease, pack-years of cigarette 
smoking and total pain, and walking tolerance during the 
GTT; i.e. there was no relationship between these variables and 
walking tolerance. There was, however, a weak but significant 
correlation between mass and PFWD during the GTT (r=0.39; 
p=0.03).
A correlation analysis was performed between total 
pain perceived on the GTT and peak venous blood lactate 
concentration and total pain perceived on the GTT and ABI. 
There was no correlation between total pain perceived on the 
GTT and peak venous blood lactate or with ABI.
Table I. Patient characteristics on entry to the  
study (mean ± SD)
Age (yrs)     63±13
BMI (kg/m2)    27±5.0
Mass (kg)     78±15
Height (m)    1.7±0.1
BF (%)     32±7
DOD (months)    26±28
Smoking (pk yrs)    23±27
MWD (m)    317±166
PFWD (m)    98±53
ABI (rest)     0.6±0.4
ABI (after exercise)    0.4±0.4
Lactate (rest) mmol/l   2.1±1.6
Lactate (after exercise) mmol/l  3.3±1.4
Yrs = years; kg = kilograms; BMI = body mass index; BF = body fat; DOD = duration 
of disease; pk yrs = pack years; MWD = maximum walking distance; PFWD = 
pain-free walking distance; m = meters; ABI = ankle brachial index; SD = standard 
deviation.
Table II. Medical history and risk factor profile of patients 
with PAD on entry to the trial
           No. of patients (%)
Peripheral arterial disease         31 (100%)
   PTA and stent          5 (16%)
   Bypass graft          2 (6%)
Coronary artery disease         14 (45%)
   History of heart failure         2 (6%)
   History of MI          6 (19%)
   History of angina pectoris         8 (26%)
   CABG           8 (26%)
   Pacemaker          1 (3%)
   Stent           1 (3%)
   PTA          1 (3%)
Cerebral vascular disease         5 (3%)
   History of transient ischaemic attack        1 (3%)
   History of stroke          1 (3%)
   Carotid endarterectomy         2 (6%)
Hypercholesterolaemia         15 (48%)
Hypertension          25 (81%)
Sedentary lifestyle          31 (100%)
Obesity           22 (71%)
Diabetes           14 (40%)
Current smoker          5 (16%)
Former smoker          18 (58%)
Respiratory disease          3 (10%)
Rheumatoid arthritis         1 (3%)
Osteoarthritis          7 (23%)
MI = myocardial infarction; CABG = coronary artery bypass graft; PTA = 
percutaneous transluminal angioplasty.
Table III. Peak oxygen consumption, peak heart rate, peak 
RER, peak venous lactate concentration and peak VE in 
patients with PAD and a control group during a maximal 
exercise test
            PVD  
           (N=31)       Cont. (N=13)
Age (yrs)           63±13       55±7*
Mass (kg)           75±15       83±10
VE (l/min)          43.0±14.2       87.5±22.1*
VO2            17.0±4.2       26.0±6*
(mlO2/kg/min)
HR (bpm)          114±22       156±11*
RER(units)          1.0±0.1       1.4±0.2*
[lacate]           3.3±1.4       9.7±2.7*
(mmol/l)
All data are presented as mean±SD.
*p<0.05 significant difference to PVD group.
Yrs = years; kg = kilogram; VE = minute ventilation; VO2 = oxygen consumption; 
HR = heart rate; bpm = beats per minute; RER = respiratory exchange ratio; PAD = 
peripheral arterial disease; Cont. = control group.
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Discussion
We found that resting ABI did not predict PFWD or MWD 
or perception of pain during the GTT. Therefore, functional 
capacity was independent of ABI, suggesting that ABI 
should not be used to predict exercise tolerance or functional 
improvement in patients with PAD. This finding agrees with a 
report that improvements in walking performance in patients 
with PAD were not accompanied by improvements in ABI.14 
If ABI cannot predict functional capacity, the use of a GTT to 
monitor functional capacity in patients with PAD may be more 
valuable than reliance on the ABI alone.
We also found that peak post-exercise venous lactate 
concentrations did not correlate with PFWD or MWD (Figs 
1a and 1b). Therefore, patients with the highest post-exercise 
venous lactate concentrations did not have the shortest PFWD 
or MWD, as might be expected if venous lactate concentrations 
are related to the development of leg pain in this condition. 
Moreover, peak venous lactate concentrations of patients with 
PAD in this study were lower (Table III) than in a control 
group. There was no correlation between total pain perceived 
on the GTT and peak venous blood lactate.
This finding is of interest as exercise physiologists and 
clinicians studying PVD commonly believe that anaerobic 
glycolysis and the resultant increase in lactate concentrations 
in the ischaemic muscles and blood explains why these 
patients develop the pain of intermittent claudication and 
why their exercise tolerance is so impaired.2,3,5 For example, 
Tan et al. stated: ‘In patients with peripheral vascular disease, 
increasing the workload causes an inequality in the supply 
of and demand for oxygen. Aerobic generation of adenosine 
triphosphate (ATP) becomes inadequate and anaerobic 
metabolism predominates. The result (of exercise) is an increase 
in lactic acid production, and a depletion of ATP and creatine 
phosphate (CP), leading to pain.’3
This explanation stems from the popular theory suggesting 
that fatigue develops as a result of anaerobiosis in the 
exercising skeletal muscles and accelerates glycolysis.15 The 
by-product of anaerobic glycolysis is lactate accumulation in 
the skeletal muscles and blood. Therefore, many studies of 
Fig. 2a. Lack of relationship between resting ABI and maximum walking distance during the
GTT. N=31 (r=0.08; p=0.30).
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Fig. 2a. Lack of relationship between resting ABI and maximum walking 
distance during the GTT (N=31; r=0.08; p=0.30).
Fig. 1a. Lack of relationship between peak post-exercise venous lactate concentration and pain-
free walking distance during GTT. N=27 (r=–0.08; p=0.33)
0
1
2
3
4
5
6
7
8
0 50 100 150 200
Pain free walking distance (m)
P
ea
k
po
st
-e
xe
rc
is
e
ve
no
us
la
ct
at
e
(m
m
ol
.L
-1
)
Fig. 1a. Lack of relationship between peak post-exercise venous lactate 
concentration and pain-free walking distance during the GTT (N=27; 
r=–0.08; p=0.33).
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Fig. 1b. Lack of relationship between peak post-exercise venous lactate concentration and
maximum walking distance during the GTT. N=27 (r=–0.03; p=0.44).
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Fig. 1b. Lack of relationship between peak post-exercise venous lactate 
concentration and maximum walking distance during the GTT (N=27; 
r=–0.03; p=0.44).
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Fig. 2b. Lack of relationship between resting ABI and pain-free walking distance during the
GTT. N=31 (r=–0.19; p=0.15).
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Fig. 2b. Lack of relationship between resting ABI and pain-free walking 
distance during the GTT (N=31; r=–0.19; p=0.15).
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patients with PAD investigated peripheral adaptations that 
may delay the onset of anaerobic glycolysis and therefore delay 
the onset of claudication and increase walking tolerance. These 
adaptations include increases in the concentration of skeletal 
muscle oxidative enzymes2,4,5 and improved oxygen extraction 
by the skeletal muscles.6,8 Lundgren et al. reported that ‘… the 
results … support the contention that an improved oxidative 
capacity is beneficial in improving PFWD. But as long as 
there is blood flow restriction, there will be a point when 
flow becomes the limiting factor producing hypoxia, lactate 
accumulation and pain.’2
It can be argued that low blood lactate concentrations could 
be associated with elevated muscle lactate concentrations in 
patients with PAD. If this is true, lactate accumulating in the 
skeletal muscle, and not in the blood, would be the direct cause 
of pain and should be measured rather than blood lactate 
concentrations to evaluate the role of lactate in the production 
of pain in this condition. However, Pernow et al. reported that 
peak muscle lactate concentrations in controls and in patients 
with PAD were equally high (13.7±1.6 v. 12.1±2.3 mmol/
kg).16 While these data seem to differ from our own, since we 
would have expected muscle lactate concentrations to be low 
(in keeping with the low blood lactate concentrations in our 
patients), Pernow et al.’s data do not support the theory that 
lactate ‘leads to pain’ (Tan et al.) as their control group did 
not experience claudication during maximal exercise despite 
similar peak muscle lactate concentrations to patients with 
PAD.3,16
In addition, our patients with PAD terminated exercise at 
lower heart rates, lower RER values and lower venous lactate 
concentrations than a sedentary control group. Patients with 
PAD also had lower VO2 and VE values than a sedentary 
control group. Therefore, perceived discomfort in these patients 
was not caused by elevated blood lactate concentrations or by 
limiting cardiorespiratory effort, but must be caused by other 
factors not measured.
Lastly, patients with PAD in this study exhibited a variety 
of other co-morbid conditions, all of which can be positively 
influenced by participation in regular physical activity 
since this reduces all-cause mortality,17 reduces the risk of 
cardiovascular disease,18,19 lowers resting blood pressure20 and 
favourably influences the blood lipid profile.21,22
Conclusion
Patients with PAD terminated exercise at low venous blood 
lactate concentrations and low levels of cardiorespiratory 
demand compared with a control group. Furthermore, no 
measured variable could predict walking distance in the 
PAD patients. Therefore, perceived discomfort and factors 
determining the walking distance of these subjects could not 
be explained on the basis of the traditional measurements 
used to predict exercise performance in healthy subjects or in 
patients with PAD. Future research should consider alternative 
explanations for this unexpected finding.
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